The content on this site is intended for healthcare professionals only
Dr Prat talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012.
Gene expression tests currently available are not an option for most of the world due to cost and assay turn around time, so Dr Prat led a team looking at gene expresssion data across 5 independent studies to try to improve pathology based biomarkers.
The study found that progesterone receptor-positive cells acted as a biomarker identifying luminal A tumours, thus enabling the identification of the sub-group of patients who may not need adjuvant systemic chemotherapy.
Gene expression data combined with pathological data improves the management of certain breast cancer patients; however issues such as cost and logistics need to be overcome.
Filming Supported by Amgen
ASCO GU 2026: Updates in metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Relapsed refractory multiple myeloma
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Loco-regional management after neoadjuvant chemotherapy
